Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial
暂无分享,去创建一个
Akshay S. Desai | S. Solomon | A. Desai | J. McMurray | K. Swedberg | J. Rouleau | G. Fonarow | M. Zile | M. Packer | B. Claggett | P. Srivastava
[1] C. Kumana,et al. Gauging the impact of statins using number needed to treat. , 1999, JAMA.
[2] J. Hausleiter,et al. Role of percutaneous edge-to-edge repair in secondary mitral regurgitation after MITRA-FR and COAPT , 2019, Clinical Research in Cardiology.
[3] Fach,et al. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.
[4] Karl Swedberg,et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.
[5] R. Touyz,et al. Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure , 2019, Pharmacological Reviews.
[6] M. Pfeffer,et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial , 2003, The Lancet.
[7] J. McMurray,et al. Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.
[8] Wing W. Chan,et al. Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction. , 2016, JAMA cardiology.
[9] Akshay S. Desai,et al. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure , 2014, European heart journal.
[10] M. Møller,et al. Is prophylaxis worse than treatment in the ICU? , 2019, Intensive Care Medicine.
[11] Akshay S. Desai,et al. Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial , 2018, JAMA cardiology.
[12] Gianni Tognoni,et al. Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-Analysis of Randomized Controlled Trials , 2006, JAMA.
[13] John L Sapp,et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. , 2010, The New England journal of medicine.
[14] Akshay S. Desai,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.
[15] R. Nelson,et al. Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction. , 2016, JACC. Heart failure.
[16] S. Solomon,et al. Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan. , 2015, The New England journal of medicine.
[17] Salim Yusuf,et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.
[18] Douglas L Packer,et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.
[19] S. Solomon,et al. Potential Mortality Reduction With Optimal Implementation of Angiotensin Receptor Neprilysin Inhibitor Therapy in Heart Failure. , 2016, JAMA cardiology.